Bolt Biotherapeutics (BOLT) Liabilities and Shareholders Equity (2020 - 2026)

Bolt Biotherapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $48.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 44.06% year-over-year to $48.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.3 million (down 41.45% YoY) and the FY2025 annual result came in at $56.7 million, down 43.04% from the prior year.
• Liabilities and Shareholders Equity slipped to $48.0 million in Q1 2026 per BOLT's latest filing, from $56.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $282.8 million in Q1 2022 and troughed at $48.0 million in Q1 2026.
• A 5-year average of $150.3 million and a median of $142.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity declined 12.89% in 2022, then slumped 44.06% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $227.8 million in 2022, then dropped by 29.86% to $159.8 million in 2023, then tumbled by 37.65% to $99.6 million in 2024, then sank by 43.04% to $56.7 million in 2025, then declined by 15.37% to $48.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $48.0 million, $56.7 million, and $65.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.